casemark/quality-agreement

Quality Agreement for Contract Manufacturing

Drafts an enforceable Quality Agreement defining quality roles, responsibilities, and cGMP compliance obligations between a product owner and a contract manufacturing organization (CMO).

Prerequisites

1. Manufacturing/supply agreement — commercial terms, product scope, facility details
2. Regulatory identifiers — FDA Establishment IDs, DUNS, DEA registrations (if controlled), ISO certs
3. Product details — dosage form, API/finished product, classification (Rx, OTC, biologic)
4. Existing quality documents — prior quality agreements, SOPs, inspection history (483s, warning letters)
5. Specifications — approved specs, analytical methods, stability protocols

Search user-uploaded documents for existing agreements, specs, and regulatory correspondence before drafting.

Output Structure

| Section | Key Contents | |---------|-------------| | Parties & Scope | Legal names, regulatory IDs, product scope, exclusions, quality-over-commercial supremacy clause | | Definitions | Regulatory terms, party-specific roles | | Quality Unit Authority | Responsibility matrix (see below), independence provisions, escalation paths | | Manufacturing & Documentation | Batch records, retention per 21 CFR 211.180, Part 11 compliance | | Change Control | Categories, approval workflows, review timelines (see below) | | Audit & Inspection | Routine/for-cause/unannounced rights, 483 response coordination | | Quality Events & CAPA | Deviation reporting, investigation, CAPA approval, recall authority | | Specifications & Release | Method validation (ICH Q2), OOS investigations, stability programs | | Personnel & Training | Qualifications, training programs, key personnel change notice | | Term & Termination | Duration, termination rights, transition obligations, survival clauses | | Appendices | Change control forms, deviation templates, quality metrics, contacts |

Quality Unit Responsibility Matrix

| Function | Product Owner | CMO | |----------|:---:|:---:| | Final batch disposition | ● | | | In-process controls execution | | ● | | Specification approval | ● | | | Deviation investigation | | ● | | Deviation report approval | ● | | | Regulatory submissions | ● | | | Environmental monitoring | | ● | | Equipment qualification | | ● | | Change control approval (major) | ● | | | Complaint handling (mfg-related) | | ● | | Recall decision authority | ● | |

Notification Timelines

| Event | Deadline | |-------|----------| | Critical quality event (safety/regulatory) | 24 hours | | Significant quality event | 72 hours | | Routine quality event | 5 business days | | Unannounced regulatory inspection | 4 hours | | Announced regulatory inspection | 24 hours | | Key personnel change | 30 days advance |

Change Control Framework

| Category | Examples | Approval | Review Period | |----------|----------|----------|---------------| | Minor | Admin SOP updates, like-for-like equipment | CMO QU (notify owner) | 15 business days | | Major | Critical process params, alt. suppliers, method revisions | Product owner QU written approval | 30 business days | | Emergency | Immediate safety/compliance | CMO implements → retrospective owner approval | Immediate |

Change proposals must include: description, scientific justification, risk assessment (FMEA/ICH Q9), validation protocols if applicable, regulatory impact analysis, implementation timeline.

Audit Rights

• Pre-approval — before manufacturing initiation
• Routine — ≤24-month intervals, 30 days advance notice
• For-cause — triggered by quality events or regulatory concerns
• Unannounced — preserved right for serious quality/regulatory concerns
• Scope — unrestricted access to batch records, validation reports, deviations, training records, personnel interviews, facility inspection
• Post-audit — report within 30 days; CMO CAPA response within 15 business days

Batch Records & Documentation

• Contemporaneous recording (indelible ink or validated electronic systems)
• Complete material genealogy and traceability
• CMO initial review: 5–10 business days post-batch completion
• Product owner QU review: 10–15 additional business days before disposition
• Retention: ≥1 year past expiry or 3 years post-distribution (whichever longer) per 21 CFR 211.180
• Part 11 compliance: system validation, audit trails, data integrity controls

Termination & Transition

• Non-renewal notice: ≥180 days before term expiry
• Material breach cure: 60 days from written notice
• Convenience termination: 180–360 days advance notice
• Post-termination: CMO supports product through shelf life (stability, reserve samples, complaints, inspections)
• Document transfer: Complete batch records and quality documentation within 90 days
• Survival: Confidentiality (indefinite), record retention (regulatory periods), regulatory support (while product in distribution)

Guidelines

• Use mandatory language ("shall," "must") — never aspirational ("should," "will")
• Include explicit quality-over-commercial supremacy clause; quality decisions independent from commercial considerations
• Align with FDA 2016 Guidance: Contract Manufacturing Arrangements for Drugs: Quality Agreements [VERIFY]
• Address data integrity per FDA 2018 Data Integrity and Compliance with Drug CGMP guidance [VERIFY]
• For international markets, incorporate ICH Q7, EU GMP Annex 11, WHO guidelines as applicable
• Include cybersecurity provisions for manufacturing systems and confidential regulatory data
• Quality agreement governs all quality matters; ensure no conflict with underlying supply agreement
• If user provides 483s or warning letters, incorporate preventive measures addressing cited deficiencies